Ovation Endograft From TriVascular

The Real World
European Experience And
Advantages

Patrick Peeters, MD
Chief, Dept. of Surgery
Chief, Dept Cardio-Vascular & Thoracic Surgery
Imelda Hospital Bonheiden (Belgium)

Disclosure
Speaker name: Patrick Peeters, MD
I have the following potential conflicts of interest to report:
- Employment in industry
- Shareholder in a healthcare company
- Owner of a healthcare company
- Other(s)
- I do not have any potential conflict of interest

History
First implementation in patients in 1991
- Dr. Juan Parodi: custom-made Dacron tube
  - Endovascular repair for AAA has gained acceptance and availability
  - Development of new commercial available devices
  - Evolution: 1st generation device until 4th generation

4th generation device:
- Excluder (GORE)
- Ovation (Trivascular)
- Zenith Flex (Cook)
- INCRAFT (Cordis)

Features of a good endoprosthesis
Treating the infrarenal aneurysm even juxtarenal AAA
- Freedom from type I or III endoleaks
- Freedom from aneurysm expansion
- Freedom from aneurysm rupture
- Need for adequate sealing, fixation
- Need for flexible device for tortuous lesions
- Need for small French size, percutaneous use

Ovation® Abdominal Stent Graft Platform
- Staged deployment of suprarenal stent allows ample, precise deployment
- Polymer-filled sealing ring creates a custom seal and protects the aortic neck
- Low permeability PTFE envelope ensures exclusion and device patency
- Conformable, kink-resistant iliac limbs designed to reduce risk of occlusion
Conclusion

- Over 5000 patients worldwide have been treated with Ovation® and Ovation Prime™ Abdominal Stent Graft Systems, with over 700 subjects in a tightly controlled study or registry
  - 161 patients enrolled in the Ovation Global Pivotal Trial
  - 77 patients enrolled in the Ovation Continued Access Trial
  - 501 patients enrolled in the OVATION Post Market European Registry
- A Post-Approval Study in the US will follow patients for 5 years
- Patient demographics, anatomical characteristics, and procedural characteristics indicate a challenging patient cohort
Conclusion

- OVATION Post Market Registries has reported encouraging clinical results in a real-world European experience.
- Safety and Performance outcomes at 1 year are promising, even for more challenging patient anatomies given a broader Intention for Use.